Welcome! You are visiting the MyeloRx web site.

Home
About Us
Contact Us
Site Map
Lead Compounds
Clinical Efficacy - Leuke
Natural Products
Our Strategy
Intellectual Property
Targets
Acute Myeloid Leukemia
Lead Compound - MRx102
MRx102
AML Xenograft Model (MV4-
Pilot Toxicity
Summary
AML Xenograft Model (MV4-11)
 
graph of data
 
 

 MRx102 Dose

(mg/kg/day)

Percent reduction in

mean tumor volume

(day 28)

0.45

 31

0.90

 55